CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.
about
Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted ApproachesUnderstanding cognitive deficits in Alzheimer's disease based on neuroimaging findingsComparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects.CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementiaImaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography.Sensitivity and specificity of diagnostic accuracy in Alzheimer's disease: a synthesis of existing evidence.CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy.T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.Usefulness of Multi-Parametric MRI for the Investigation of Posterior Cortical Atrophy.Liquid chromatography with tandem mass spectrometry-based proteomic discovery in aging and Alzheimer's disease.The heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer's diseaseInvolvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer's disease.Biomarkers of HIV related central nervous system disease.The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients.Role of phosphodiesterase 5 in synaptic plasticity and memoryBiomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood.Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a reviewBiomarkers of Alzheimer's disease in body fluids.What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease.Management of cognitive determinants in senile dementia of Alzheimer's type: therapeutic potential of a novel polyherbal drug product.CSF p-Tau levels in the prediction of Alzheimer's disease.Immunocytochemical characterization of Alzheimer disease hallmarks in APP/PS1 transgenic mice treated with a new anti-amyloid-β vaccine.Vaccine Development to Treat Alzheimer's Disease Neuropathology in APP/PS1 Transgenic Mice.Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: evidence for novel Abeta species.Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease.Antipsychotic medication is associated with selective alterations in ventricular cerebrospinal fluid Aβ 40 and tau in patients with intractable unipolar depression.Tau and Amyloid-β Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment.[The future of biomarkers in dementia diagnostics].Ultra-sensitive detection of protein biomarkers for diagnosis of Alzheimer's diseaseDecreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer's Disease
P2860
Q26770708-624B9B69-7292-4F39-921B-1EFDD81414EBQ30666527-13ECFA05-C533-4F75-9D83-F394DE362846Q33237201-DA001845-AC10-4DFD-9E0F-12EC053D74EDQ33239180-66B2A3F3-5D97-4F59-9449-B3BDA585C0AAQ34378321-9A2B478E-1BFB-434A-AD22-26D490F97947Q34728483-E441DAE4-82A5-4F77-B4D2-94FB999ADE7EQ35114771-76829AAA-0B52-47C8-AD37-AA17DA96D3E3Q35221966-5B2E076E-0E84-4018-9805-8B2CBB3E6175Q35812786-0D034351-12B8-4A0A-8027-942EDAEBACFFQ36525167-7A7FDF3B-D90F-456E-9036-B58E8B4E8E91Q36660120-D4F2D2CE-D0EF-49B9-A860-677030FB7C54Q36688776-B7A0BD97-4E30-47C0-93BA-CC1F56AEB1B5Q37073672-C2228F6E-709A-4E73-92AF-4CDF36B5FAACQ37166782-FF1DBD90-3A10-44E4-AB79-CE7BCDA8502DQ37252748-8B54B867-55DD-4474-B1C7-3779E4FEB69DQ37273675-0B881293-5692-4481-AFD9-5DF585FB4A81Q37418238-10C73EA3-4ED5-4EFF-AAB3-7D6BA19E4BF2Q37769463-696E4DEB-8DEF-4A7F-98BE-21A333C466E8Q38088747-F838528E-346F-49F9-80A3-21D52F12BB55Q40228913-AD4B928E-E8F0-4E1E-9D5A-E68BA83EEDE1Q41845685-2631775D-303F-40CB-A4E1-4341110CC62BQ42073963-DAFF12FE-B939-4254-A94D-93D8F96EC018Q42513498-4F052368-D328-4E89-B9B2-DBE84EDA4EC2Q46959711-93CCC0D5-7CE0-4F14-82A5-551DEDE2D72EQ47407570-1E9DBEF7-1077-4EB1-932F-669F79AAFA46Q48913533-BD9FDDE9-E745-4E9C-A429-AC733C329554Q50244334-7AA0EBAB-18C1-4EAD-98AA-75FB89B9BBADQ53322182-86D89EFF-63F1-4548-9F91-EE1157440DFBQ58376432-96A12EE7-02E3-40C8-9B51-1AF3D8203C87Q58758801-EEE85B03-A975-48C4-8022-CDE9982090D3
P2860
CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.
@ast
CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.
@en
type
label
CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.
@ast
CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.
@en
prefLabel
CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.
@ast
CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.
@en
P2860
P1476
CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.
@en
P2093
Niels Andreasen
P2860
P304
P356
10.1080/15622970310029912
P577
2003-10-01T00:00:00Z